COMMUNIQUÉS West-GlobeNewswire

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
26/03/2024
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and [...]
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika
26/03/2024
Saint-Herblain (France), le 26 mars 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour évaluer l’innocuité et l’ [...]
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion
26/03/2024
CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion Clermont-Ferrand, France, Tuesday 26 March 2024 (06.45am CET) CARBIOS (Euronext Growth Paris: ALCRB), a [...]
CARBIOS rejoint Paris Good Fashion pour accélérer la circularité des textiles et contribuer à une mode plus durable
26/03/2024
CARBIOS rejoint Paris Good Fashion pour accélérer la circularité des textiles et contribuer à une mode plus durable Clermont-Ferrand (France), le mardi 26 mars 2024 (06h45 CET). CARBIOS , (Euronext Growth Paris : ALCRB [...]
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
26/03/2024
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company [...]
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25/03/2024
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured [...]
Precipio Announces Year end 2023 Shareholder Update Call
25/03/2024
Conference Call to be held on April 1st, 2024 at 5:00 PM EDT NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its year end 2023 [...]
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
25/03/2024
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12 th participant on March 23, 2024, in the Company’s ongoing Phase 2 [...]
Ibogaine By David Dardashti Explains the Legal Status of Ibogaine
25/03/2024
Ibogaine Therapy Provides an Effective Cure for Opiate Addiction MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Ibogaine by David Dardashti is proud to announce more information about the legal status of ibogaine in Mexico [...]
Goodness Growth Holdings Reschedules Fourth Quarter and Full Year 2023 Results Call to April 1, 2024
25/03/2024
MINNEAPOLIS, March 25, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and [...]
Agile Therapeutics Announces Delisting from Nasdaq
25/03/2024
PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final [...]
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
25/03/2024
CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23 rd [...]
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
25/03/2024
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity [...]
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
25/03/2024
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase 2b portion and [...]
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
25/03/2024
FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
25/03/2024
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology [...]
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
25/03/2024
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The additional Phase 1 SNK01 trial data suggest clinical activity [...]
OpGen Announces Acquisition of Preferred Stock by David Lazar
25/03/2024
David Lazar invests $3 million in Preferred Stock New OpGen Board of Directors appointed David Lazar will take over as CEO of OpGen OpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE [...]
Praxis Precision Medicines to Host PRAX-628 Program Update
25/03/2024
Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of [...]

Pages